Eli Lilly and Company v Pfizer Ireland Pharmaceuticals (No 2)

Link copied
Case Copied 6 min read

FEDERAL COURT OF AUSTRALIA

Eli Lilly & Company v Pfizer Ireland Pharmaceuticals (No 2) [2004] FCA 850

INTELLECTUAL PROPERTY – privilege of registered patent attorneys – whether extending to communications with patent attorneys not registered in Australia

WORDS AND PHRASES – “registered patent attorney”

Patents Act 1990 (Cth), s 200(2)
Federal Court Rules O 33 r 12

Wilden Pump Engineering Co v Funfeld [1985] FSR 159 at 168 applied
Pfizer Pty Ltd v Warner Lambert Pty Ltd (1989) 24 FCR 47 applied
Kennedy v Wallace [2004] FCA 332 at [57] referred to

ELI LILLY AND COMPANY & ORS V PFIZER IRELAND PHARMACEUTICALS & ANOR (No 2)
V604 OF 2002

HEEREY J
30 JUNE 2004
MELBOURNE


IN THE FEDERAL COURT OF AUSTRALIA

VICTORIA DISTRICT REGISTRY

V604 OF 2002

BETWEEN:

ELI LILLY AND COMPANY
FIRST APPLICANT/FIRST CROSS-RESPONDENT

ELI LILLY AUSTRALIA PTY LTD (ACN 000 233 992)
SECOND APPLICANT/SECOND CROSS-RESPONDENT

ELI LILLY AND COMPANY LIMITED
THIRD APPLICANT/THIRD CROSS-RESPONDENT

AND:

PFIZER IRELAND PHARMACEUTICALS
FIRST RESPONDENT/FIRST CROSS-CLAIMANT

PFIZER PTY LIMITED (ACN 008 422 348)
SECOND RESPONDENT/SECOND CROSS-CLAIMANT

JUDGE:

HEEREY J

DATE OF ORDER:

30 JUNE 2004

WHERE MADE:

MELBOURNE

THE COURT ORDERS THAT:

  1. The respondents/ cross-claimants produce to the applicants/ cross-respondents the documents identified as items 1 and 2 in the Notice to Produce dated 24 June 2004
  2. The respondents/ cross-claimants pay the applicants/ cross-respondents’ costs of today’s hearing.

Note:    Settlement and entry of orders is dealt with in Order 36 of the Federal Court Rules.


IN THE FEDERAL COURT OF AUSTRALIA

VICTORIA DISTRICT REGISTRY

V604 OF 2002

BETWEEN:

ELI LILLY AND COMPANY
FIRST APPLICANT/FIRST CROSS-RESPONDENT

ELI LILLY AUSTRALIA PTY LTD (ACN 000 233 992)
SECOND APPLICANT/SECOND CROSS-RESPONDENT

ELI LILLY AND COMPANY LIMITED
THIRD APPLICANT/THIRD CROSS-RESPONDENT

AND:

PFIZER IRELAND PHARMACEUTICALS
FIRST RESPONDENT/FIRST CROSS-CLAIMANT

PFIZER PTY LIMITED (ACN 008 422 348)
SECOND RESPONDENT/SECOND CROSS-CLAIMANT

JUDGE:

HEEREY J

DATE:

30 JUNE 2004

PLACE:

MELBOURNE

REASONS FOR JUDGMENT

  1. The applicants/cross-respondents Eli Lilly and Company and Eli Lilly Australia Pty Ltd (collectively Lilly) have given a notice to produce under O 33 r 12 of the Federal Court Rules requiring production of the following documents which have been discovered by the respondents/cross-claimants Pfizer Ireland Pharmaceuticals and Pfizer Pty Limited (collectively Pfizer):

    “1.Document entitled ‘Record of inventorship UK Patent Application No 9311920.4’ (identified in the Respondent’s discovery as PIP.3229.0001) from N.Terett and P. Ellis dated 22 June 1993;

    2.Document entitled ‘Request for Patent Application – The use of cGMP PDE inhibitors for impotence’ (identified in the Respondent’s discovery as PIP.3229.0002) dated 18 January 1993;”

  2. Pfizer has resisted production on the basis that the documents were brought into existence for the dominant purpose of obtaining advice from its in-house patent attorneys in the United Kingdom.  In the course of argument senior counsel also relied on what he said was a “cloak of confidentiality analogous to privilege”. 

  3. Section 200(2) of the Patents Act 1990 (Cth) (the Act) provides:

    “(2)  A communication between a registered patent attorney and the attorney’s client in intellectual property matters, and any record or…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Eli Lilly and Company v Pfizer Ireland Pharmaceuticals (No 2... and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2004] FCA 850
Decision Date

CaseChat Overview and Summary

Eli Lilly and Company, the originator of a pharmaceutical patent, sought an order for the respondents, Pfizer Ireland Pharmaceuticals and its related companies, to produce documents. The case revolved around the validity and infringement of a patent for a pharmaceutical compound. The matter was heard in the Federal Court of Australia.

The primary legal issue was whether the respondents were required to disclose the documents identified in the Notice to Produce. The court had to determine the extent of disclosure obligations under the Australian Patent Act and the relevant case law. Another aspect considered was whether the respondents had legitimate grounds to resist disclosure based on confidentiality or privilege.

The court found that the documents in question were pertinent to the patent validity and infringement issues at hand. It held that the respondents were obliged to produce the documents as they were relevant to the proceedings. The court rejected the respondents' argument that the documents were subject to legal professional privilege. The Federal Court ordered the respondents to produce the specified documents and to pay the costs of the hearing.

Orders

Orders of the court

1. The respondents/ cross-claimants produce to the applicants/ cross-respondents the documents identified as items 1 and 2 in the Notice to Produce dated 24 June 2004

2. The respondents/ cross-claimants pay the applicants/ cross-respondents’ costs of today’s hearing.

Background

Background to the litigation

Evidence

Evidence Before The Court

Decision

Reasons for decision

HEEREY J

Ratio Decidendi

Legal Principle Established

Established by: HEEREY J